Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
08:33:31 EST Sun 08 Feb 2026
Enter Symbol
or Name
USA
CA



Q:ESPR - ESPERION THERAPEUTICS INC - https://www.espr.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
ESPR - Q0.12.00·3.650.23.40+0.226.94,765.515,45110,7523.25  3.45  3.224.175  0.69319:22:53Jan 1115 min RT 2¢

Recent Trades - Last 10 of 10752
Time ETExPriceChangeVolume
19:22:53Q3.39020.21022
17:45:34Q3.400.22500
17:17:09Q3.370.191
16:35:49Q3.370.191
16:10:04Q3.400.221
16:04:03Q3.400.221
16:04:03Q3.400.221
16:01:42Q3.400.225,665
16:01:17Q3.400.222,756
16:01:16Q3.400.22898

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-01-11 18:00U:ESPRNews ReleaseEsperion Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference
2026-01-05 08:00U:ESPRNews ReleaseEsperion to Participate in Upcoming 44th Annual J.P. Morgan Healthcare Conference
2025-12-19 08:00U:ESPRNews ReleaseEsperion's Bempedoic Acid Receives Recommendation in 2025 ACC Scientific Statement on Management of Peripheral Artery Disease in Adults With Diabetes
2025-12-09 16:30U:ESPRNews ReleaseEsperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2025-11-21 08:00U:ESPRNews ReleaseEsperion Partner Otsuka Launches NEXLETOL(TM) in Japan for the Treatment of Hypercholesterolemia
2025-11-19 08:00U:ESPRNews ReleaseEsperion to Participate in Piper Sandler 37th Annual Healthcare Conference
2025-11-18 07:00U:ESPRNews ReleaseHLS Therapeutics Announces Health Canada Approval of NILEMDO(TM) for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease
2025-11-18 07:00U:ESPRNews ReleaseEsperion Partner HLS Therapeutics Announces Approval of NILEMDO(TM) for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease
2025-11-10 08:00U:ESPRNews ReleaseEsperion Announces New Data from CLEAR Outcomes Highlighting Value of NEXLETOL(TM) (bempedoic acid) in Oral and Poster Presentations at the AHA Scientific Sessions 2025
2025-11-06 16:30U:ESPRNews ReleaseEsperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2025-11-06 06:00U:ESPRNews ReleaseEsperion Reports Third Quarter 2025 Financial Results and Provides Business Update
2025-11-04 08:00U:ESPRNews ReleaseEsperion Appoints Industry Veteran John Harlow as Chief Commercial Officer
2025-11-03 08:00U:ESPRNews ReleaseEsperion to Participate in Jefferies Global Healthcare Conference - London
2025-10-28 08:00U:ESPRNews ReleaseEsperion to Host Virtual Investor Key Opinion Leader Event Highlighting Significant Unmet Need in Statin Intolerance on Tuesday, November 11, 2025, at 2:00 p.m. ET.
2025-10-27 08:00U:ESPRNews ReleaseEsperion Announces New Analyses from CLEAR Outcomes to be Presented at the American Heart Association (AHA) Scientific Sessions 2025
2025-10-23 08:00U:ESPRNews ReleaseEsperion to Report Third Quarter 2025 Financial Results on November 6
2025-10-16 08:00U:ESPRNews ReleaseEsperion Nominates ESP-2001 as Preclinical Development Candidate for Treatment of Primary Sclerosing Cholangitis
2025-10-07 21:29U:ESPRNews ReleaseEsperion Announces Pricing of Public Offering of Common Stock
2025-10-07 16:02U:ESPRNews ReleaseEsperion Announces Proposed Public Offering of Common Stock
2025-10-03 08:00U:ESPRNews ReleaseEsperion Reaches Settlement Agreement with ANDA Filer, Dr. Reddy's Laboratories, Not to Market Generic Versions of NEXLETOL(TM) (bempedoic acid) and NEXLIZET(TM) (bempedoic acid and ezetimibe) Prior to April 19, 2040